Patient demographics and baseline disease characteristics (intent-to-treat population)
Parameter . | VR-CAP, n = 84 . | R-CHOP, n = 80 . | ||
---|---|---|---|---|
n . | % . | n . | % . | |
Age, y | ||||
Median | 59.5 | 58.5 | ||
Range | 20-84 | 23-83 | ||
Age >65 y | 26 | 31 | 26 | 33 |
Gender | ||||
Male | 41 | 49 | 47 | 59 |
Race | ||||
White | 64 | 76 | 52 | 65 |
Asian | 15 | 18 | 14 | 18 |
Other | 5 | 6 | 14 | 18 |
ECOG performance status | ||||
0/1 | 73 | 87 | 64 | 80 |
2 | 11 | 13 | 16 | 20 |
IPI* | ||||
Low (0 or 1) | 21 | 25 | 20 | 25 |
Low-intermediate (2) | 20 | 24 | 19 | 24 |
High-intermediate (3) | 27 | 32 | 26 | 33 |
High (4 or 5) | 16 | 19 | 15 | 19 |
Disease stage at study entry | ||||
I/II | 23 | 27 | 18 | 22 |
III/IV | 61 | 73 | 62 | 78 |
Symptomatic disease | 54 | 64 | 57 | 71 |
Parameter . | VR-CAP, n = 84 . | R-CHOP, n = 80 . | ||
---|---|---|---|---|
n . | % . | n . | % . | |
Age, y | ||||
Median | 59.5 | 58.5 | ||
Range | 20-84 | 23-83 | ||
Age >65 y | 26 | 31 | 26 | 33 |
Gender | ||||
Male | 41 | 49 | 47 | 59 |
Race | ||||
White | 64 | 76 | 52 | 65 |
Asian | 15 | 18 | 14 | 18 |
Other | 5 | 6 | 14 | 18 |
ECOG performance status | ||||
0/1 | 73 | 87 | 64 | 80 |
2 | 11 | 13 | 16 | 20 |
IPI* | ||||
Low (0 or 1) | 21 | 25 | 20 | 25 |
Low-intermediate (2) | 20 | 24 | 19 | 24 |
High-intermediate (3) | 27 | 32 | 26 | 33 |
High (4 or 5) | 16 | 19 | 15 | 19 |
Disease stage at study entry | ||||
I/II | 23 | 27 | 18 | 22 |
III/IV | 61 | 73 | 62 | 78 |
Symptomatic disease | 54 | 64 | 57 | 71 |
ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index.
Percentages may not equal 100% due to rounding.